FRX vs. CRON, SLS, TEV, ABT, NOT, PYR, NVO, DNA, ITH, and VBV
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Cronos Group (CRON), Solaris Resources (SLS), Tervita (TEV), Absolute Software Co. (ABT.TO) (ABT), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), Dalradian Resources (DNA), International Tower Hill Mines (ITH), and VBI Vaccines (VBV). These companies are all part of the "pharmaceutical products" industry.
Fennec Pharmaceuticals vs. Its Competitors
Cronos Group (TSE:CRON) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.
In the previous week, Cronos Group had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 2 mentions for Cronos Group and 1 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 0.67 beat Cronos Group's score of 0.11 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.
Cronos Group has a beta of 1.208662, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 2.091843, indicating that its stock price is 109% more volatile than the S&P 500.
Fennec Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.
4.7% of Cronos Group shares are held by institutional investors. Comparatively, 14.2% of Fennec Pharmaceuticals shares are held by institutional investors. 46.4% of Cronos Group shares are held by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Fennec Pharmaceuticals has a net margin of -2.30% compared to Cronos Group's net margin of -42.65%. Fennec Pharmaceuticals' return on equity of 29.94% beat Cronos Group's return on equity.
Summary
Fennec Pharmaceuticals beats Cronos Group on 10 of the 15 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:FRX) was last updated on 9/13/2025 by MarketBeat.com Staff
